Loading provider…
Loading provider…
Hematology & Oncology Physician in San Francisco, CA
NPI: 1043373681Primary Practice Location
UCSF MEDICAL CENTER
1975 4th St, San Francisco, CA
Primary Employer
UCSF Medical Center
ucsfhealth.org
HQ Phone
Get MD Rebecca's Phone Numberphone_androidMobile
Get MD Rebecca's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2009 - 2026
PA State Medical License
2003 - 2010

American Board of Internal Medicine
Medical Oncology
Perelman School of Medicine - Philadelphia
med.upenn.edu
Medical School
Until 2003
University of Pennsylvania Health System
Fellowship • Hematology and Medical Oncology
2006 - 2009
Residency • Internal Medicine
2003 - 2006
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 64 | 157 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 60 | 91 |
| 3 | 38222Bone marrow biopsy and aspiration | 37 | 41 |
| 4 | 99205New patient office or other outpatient visit, typically 60 minutes | 21 | 21 |
| 5 | G2212Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 14 | 23 |
Inflammatory biomarkers and patient-reported outcomes in acute myeloid leukemia: Refocusing on older adults.
Authors: Li-wen Huang, Rebecca Olin
Publication Date: 2019-07-03
Authors: @ValidYN, LastName, ForeName, Initials, AffiliationInfo
Journal: Hematology Am Soc Hematol Educ Program
Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results.
Authors: Lloyd Damon, Matthew Wieduwilt, Karin Gaensler
Publication Date: 2019-01-15
Lead Sponsor: Fred Hutchinson Cancer Center
Collaborators: National Institutes of Health (NIH), National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Questionnaire Administration, OTHER: Quality-of-Life Assessment, OTHER: Survey Administration, OTHER: Best Practice, PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation, OTHER: Supportive Palliative Care, OTHER: Clinical Management
Lead Sponsor: Ronald Hoffman
Collaborators: National Cancer Institute (NCI), Roche Pharma AG, Myeloproliferative Disorders-Research Consortium
Intervention / Treatment: DRUG: Aspirin, DRUG: Hydroxyurea, DRUG: PEGASYS
Lead Sponsor: Ronald Hoffman
Collaborators: National Cancer Institute (NCI), Roche Pharma AG, Myeloproliferative Disorders-Research Consortium
Intervention / Treatment: DRUG: Aspirin, DRUG: PEGASYS